Yoda Therapeutics Inc.
Update：2024/08/05
Industries
Main Industry
Biotechnology
Main Product/Service
Neurology
Pipeline
Utilizing Yoda’s proprietary AI-based drug screening platform, we engage in the exploration and development of promising and beneficial products to address unmet medical needs, instilling new hope in patients.YA-101 Multiple System Atrophy
YA-102 Parkinson's Disease
YA-201 Alzheimer's Disease
Neuropsychiatry
YA-301
Schizophrenia
YA-401 Autism
Cerebrovascular Disease
YA-501 Ischemic Stroke
YA-502
Traumatic Brain Injury
Pipeline
Utilizing Yoda’s proprietary AI-based drug screening platform, we engage in the exploration and development of promising and beneficial products to address unmet medical needs, instilling new hope in patients.YA-101 Multiple System Atrophy
YA-102 Parkinson's Disease
YA-201 Alzheimer's Disease
Neuropsychiatry
YA-301
Schizophrenia
YA-401 Autism
Cerebrovascular Disease
YA-501 Ischemic Stroke
YA-502
Traumatic Brain Injury
Founded Year
2022
Unified Business No.
89116715
Status
Active
Number of Employees
0
Total Paid-in
Capital
773,881,600 (NT$)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Location of Company
Taiwan
, Taipei City
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Yoda Pharmaceuticals Inc. was founded in 2019 through a collaboration of researchers from National Taiwan University, National Yang Ming Chiao Tung University, and the National Health Research Institutes, along with psychiatric physicians in practice. Incubated through Taiwan's national initiative and Stanford University's global SPARK program, Yoda is a pharmaceutical company specializing in the use of state-of-the-art AI technology for the development of innovative drugs targeting Central Nervous System (CNS) disorders.
YA-101, Yoda's flagship drug, received orphan drug designation for Multiple System Atrophy (MSA) from the U.S. Food and Drug Administration (FDA) in 2022 and has entered phase I clinical trials. In addition, Yoda’s development pipeline includes new durgs in the field of neurological and psychiatric disorders and cerebrovascular diseases, targeting conditions such as schizophrenia, Alzheimer's disease, Parkinson‘s disease, Autism, ischemic stroke, and traumatic brain injury . Driven by a mission to address unmet medical needs, we are dedicated to offering new treatment options that are innovative, effective, safe, and convenient.
YA-101, Yoda's flagship drug, received orphan drug designation for Multiple System Atrophy (MSA) from the U.S. Food and Drug Administration (FDA) in 2022 and has entered phase I clinical trials. In addition, Yoda’s development pipeline includes new durgs in the field of neurological and psychiatric disorders and cerebrovascular diseases, targeting conditions such as schizophrenia, Alzheimer's disease, Parkinson‘s disease, Autism, ischemic stroke, and traumatic brain injury . Driven by a mission to address unmet medical needs, we are dedicated to offering new treatment options that are innovative, effective, safe, and convenient.
